We aim to drive the development of our business through technological innovation. We believe cell culture is an integral part of the industry chain. Based on the culture medium's action and optimization, the fully integrated upstream and downstream technology research and development capabilities of CMC are vital to working with biopharmaceutical partners. The R&D Center is the core department of QuaCell Biotechnology. We invest at least 20% of our sales in innovative technology research; 67.5% of our employees are R&D personnel, among which 11% are PhDs, and 15% are masters.
Our R & D center is mainly dedicated to continuously improving serum-free media and cell culture process optimization capabilities and providing systematic solutions for domestic and foreign biopharmaceutical companies. Simultaneously, the R&D center has complete system R&D capabilities, equipment, and platforms and has the design and development capabilities for cell line construction, medium development, medium manufacturing, CMC research, and clinical sample production. Also, the R&D center upholds the concept that quality comes from the design and uses experiments and data to scientifically guide biotechnology product design, process flow, process control, and other aspects to provide technical support for the steady development of the company.